When was Epicrispr Bio founded?

Epicrispr Bio was founded in 2018 and raised its 1st funding round 7 years after it was founded.

Where is Epicrispr Bio located?

Epicrispr Bio is headquartered in San Francisco, United States.

Who is the current CEO of Epicrispr Bio?

Amber Salzman of Epicrispr Bio.

How many employees does Epicrispr Bio have?

As of Jul 31, 2026, the latest employee count at Epicrispr Bio is 49.

Is Epicrispr Bio a funded company?

Epicrispr Bio is a funded company, having raised a total of $158M across 2 funding rounds to date. The company's 1st funding round was a $***** Series B round, raised on Mar 27, 2025.

When was the latest funding round of Epicrispr Bio?

Epicrispr Bio's latest funding was a $***** Series C round on Aug 11, 2026, with participation from 9 investors.

Where does Epicrispr Bio rank among its competitors?

Epicrispr Bio ranks 100th amongst 945 active competitors, of which 323 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Epicrispr Bio, which secured $68M in Mar, 2025.

Who are the top competitors of Epicrispr Bio?

Epicrispr Bio's top competitors include BridgeBio, Alnylam and Biogen. Among them, Epicrispr Bio secured the most recent funding round in August, 2026.

Epicrispr Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.

Website: epicrispr.com
Social
Phone Number: +1 **********

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series C

Total Funding

$158M in 2 rounds

Latest Funding Round

Series C, Aug 11, 2026, $*****

Investors

Ally Bridge Group & 2 more

Ranked

100^th among 945 active competitors

Employee Count

49 as on Jul 31, 2026

Similar Companies

BridgeBio & 1123 more

View Epicrispr Bio's full profile

Epicrispr Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EPICRISPR BIOTECHNOLOGIES, INC CIN: 824177431 , United States, Active	Dec 31, 1999	-	38 (As on Dec 31, 2024)	-

Epicrispr Bio has raised a total funding of $158M over 2 rounds. Its first funding round was on Mar 27, 2025. Its latest funding round was a Series C round on Aug 11, 2026 for $*****. 9 investors participated in its latest round. Epicrispr Bio has 3 institutional investors.

Here is the list of recent funding rounds of Epicrispr Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 11, 2026	5442364	Series C	6329521	6747829	8834317	7157409
Mar 27, 2025	1804035	Series B	8319833	9650865	Ally Bridge Group	Solve FSHD

Access funding benchmarks and valuations. Sign up today!

View details of Epicrispr Bio's funding rounds and investors

The founders of Epicrispr Bio is Lei Stanley Qi. Amber Salzman is the CEO of Epicrispr Bio.

Here are the details of Epicrispr Bio's key team members:

Lei Stanley Qi: Founder of Epicrispr Bio and founder of 1 other company.
Amber Salzman: CEO of Epicrispr Bio.
Contact Info: 1 email address

View details of Epicrispr Bio's Founder profiles and Board Members

Epicrispr Bio's employee count trend

Epicrispr Bio has 49 employees as of Jul 26. Here is Epicrispr Bio's employee count trend over the years:

Uncover Epicrispr Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epicrispr Bio include BridgeBio, Alnylam and Biogen. Here is the list of Top 10 competitors of Epicrispr Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	KKR, Viking Global Investors & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
6th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
7th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
8th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
9th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, RA Capital Management & 7 others	70/100
10th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
100th	Epicrispr Bio 2018, San Francisco (United States), Series C	Developer of therapeutics for multiple disease	$158M	LDV Partners, Ally Bridge Group & 1 others	62/100